UNSPSC 51432002: Bencyclane

This classification denotes a calcium channel blocker with the molecular formula C19H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6I97Z6S135, chemically known as 3-((1-benzylcycloheptyl)oxy)-n,n-dimethylpropylamin but generally known as bencyclane, which bears US NIH Compound Identifier 2312. Bencyclane most often comes in base and fumarate forms. European Medicines Agency schedules Bencyclane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05705MIG.

UNSPSC 51432002 Bencyclane is a Commodity code covering pharmaceutical active ingredients and finished medications supplied to state and local health systems, emergency services, and benefit programs. State and local governments procure emergency medications, maintenance drugs, and over-the-counter products under this code to stock hospitals, fire rescue services, pharmacy benefit programs, and public health facilities. The issuing bodies include city purchasing departments (fire rescue), state health and human services commissions, and multi-state cooperative purchasing alliances representing state departments and participating municipalities. Scope ranges from sealed-bid procurements for specific vial counts and expiration-date requirements to cooperative-purchasing RFPs establishing multi-year contracts with tiered pricing and wholesaler-chargeback systems, and exploratory RFIs gathering vendor capabilities for direct-to-manufacturer prescription fulfillment models.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted IFB 26P00188 on April 24, 2026 (response deadline April 8, 2026) to supply Advanced Life Support Medications—370 units Labetalol HCI, 1,810 units Epinephrine, 330 units Adenosine, and 1,020 units Diltiazem—to Tampa Fire Rescue at an estimated contract value of $40,000, with a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation. The Texas Health and Human Services Commission issued RFI HHS0017013 (April 3, 2026 deadline) to explore vendor capacity for direct-to-manufacturer prescription programs outside traditional PBM and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 with a March 26, 2026 response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local facilities across Minnesota and Oregon, with evaluation weighted 75 percent on price competitiveness and contract effective July 1, 2026.